文献速递慢性肾脏病

自体肾细胞疗法稳定糖尿病相关慢性肾脏病功能:细胞标志物分析印证其机制作用

Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action With Cell Marker Analysis.
PubMed 文献 · Kidney Int Rep · 2022-04-21

本研究纳入22例晚期2型糖尿病相关慢性肾脏病成人,接受肾活检后两次肾皮质下注射自体同源选择性肾细胞(REACT),间隔7±3个月,其中2例仅注射1次。注射后年化eGFR斜率由注射前-4.63改善至-1.69 ml/min per 1.73 m2 per year(P=0.015)。细胞标志物分析提示选择性肾细胞可能使REACT稳定并改善肾功能。

要点

  • 22例2型糖尿病相关CKD患者接受REACT注射,年化eGFR斜率由-4.63改善至-1.69 ml/min per 1.73 m2 per year(P=0.015)。
  • 注射后7例患者eGFR斜率>0 ml/min per 1.73 m2。
  • 选择性肾细胞表达输尿管芽、间充质帽及足细胞来源标志物且VEGF阳性。

核心结论

  • 细胞标志物分析提示选择性肾细胞可能使REACT稳定并改善肾功能,可能阻止2型糖尿病相关CKD进展。

研究设计与样本

  • 22例晚期2型糖尿病相关慢性肾脏病成人接受肾活检后行2次肾皮质下选择性肾细胞注射,间隔7±3个月,其中2例仅注射1次。
  • 采用2009 CKD-EPI血肌酐公式及2012 CKD-EPI肌酐-胱抑素C公式比较REACT注射前后年化eGFR斜率,并报告临床与实验室变化。
  • 对REACT中肾脏祖细胞谱系行荧光激活细胞分选分析,并分析供体血管内皮生长因子A。
  • 纵向参数变化采用纵向线性混合效应模型分析。

主要发现

  • 基线时糖尿病病程均值18.4±8.80年,糖化血红蛋白7.0±1.05,采用2012 CKD-EPI胱抑素C与血肌酐公式的eGFR为40.3±9.35 ml/min per 1.73 m2。
  • 年化eGFR斜率(2012 CKD-EPI)注射前为-4.63 ml/min per 1.73 m2 per year,注射后改善至-1.69 ml/min per 1.73 m2 per year(P=0.015)。
  • 注射后有7例患者eGFR斜率>0 ml/min per 1.73 m2。
  • 选择性肾细胞被发现具有输尿管芽、间充质帽及足细胞来源的细胞标志物且VEGF阳性。
  • 有2例患者发生远期致死性不良事件,判定与活检/注射或REACT产品无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) is a worldwide disease without cure. Selected renal cells (SRCs) can augment kidney function in animal models. This study correlates the phenotypical characteristics of autologous homologous SRCs (formulated product called Renal Autologous Cell Therapy [REACT]) injected into patients' kidneys with advanced type 2 diabetes-related CKD (D-CKD) to clinical and laboratory findings. METHODS: A total of 22 adults with type 2 D-CKD underwent a kidney biopsy followed by 2 subcortical injections of SRCs, 7 ± 3 months apart. There were 2 patients who had only 1 injection. We compared annualized estimated glomerular filtration rate (eGFR) slopes pre- and post-REACT injection using the 2009 CKD-EPI formula for serum creatinine (sCr) and the 2012 CKD-EPI Creatinine-Cystatin C equation and report clinical/laboratory changes. Fluorescent Activated Cell Sorting (FACS) Analysis for renal progenitor lineages in REACT and donor vascular endothelial growth factor A (VEGF-A) analysis were performed. Longitudinal parameter changes were analyzed with longitudinal linear mixed effects model. RESULTS: At baseline, the mean diabetes duration was 18.4 ± 8.80 years, glycated hemoglobin (Hgb) was 7.0 ± 1.05, and eGFR was 40.3 ± 9.35 ml/min per 1.73 m2 using the 2012 CKD-EPI cystatin C and sCr formulas. The annualized eGFR slope (2012 CKD-EPI) was -4.63 ml/min per 1.73 m2 per year pre-injection and improved to -1.69 ml/min per 1.73 m2 per year post-injection (P = 0.015). There were 7 patients who had an eGFR slope of >0 ml/min per 1.73 m2 postinjection. SRCs were found to have cell markers of ureteric bud, mesenchyme cap, and podocyte sources and positive VEGF. There were 2 patients who had remote fatal adverse events determined as unrelated with the biopsies/injections or the REACT product. CONCLUSION: Our cell marker analysis suggests that SRCs may enable REACT to stabilize and improve kidney function, possibly halting type 2 D-CKD progression.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Stavas J, Filler G, Jain D, et al. Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action With Cell Marker Analysis. Kidney Int Rep. 2022. PMID: 35812284. doi:10.1016/j.ekir.2022.04.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。